Pomerantz LLP Investigates Potential Securities Claims Against PepGen Inc.
New York, NY, February 5, 2025
Pomerantz LLP, a leading securities law firm, is investigating potential securities claims on behalf of investors of PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). The investigation concerns possible violations of federal securities laws, specifically related to alleged misrepresentations and/or omissions in the Company’s public statements and filings.
Background on PepGen
PepGen is a clinical-stage biotechnology company focused on developing therapeutics using its proprietary mRNA technology. The Company’s lead product candidate, PepMab-101, is being developed for the treatment of multiple myeloma and other B-cell malignancies.
Allegations Against PepGen
The investigation focuses on whether PepGen and certain of its executives and directors made false and/or misleading statements and/or failed to disclose material information to investors. Specifically, there are concerns regarding the Company’s clinical trial data for PepMab-101 and its regulatory interactions with the U.S. Food and Drug Administration (FDA).
Impact on Investors
If it is determined that PepGen and its executives and directors misrepresented or omitted material information, investors may be able to recover their losses through a securities class action lawsuit. Such a lawsuit could result in significant compensation for affected investors.
Global Implications
Beyond the impact on individual investors, the outcome of this investigation could have far-reaching implications for the biotechnology industry as a whole. If it is found that PepGen engaged in misconduct, it could lead to increased scrutiny of other companies in the sector and potentially deter investment in the industry.
Additional Sources
According to other online sources, the investigation was initiated after a series of reports raised concerns about the validity of PepGen’s clinical trial data for PepMab-101. The FDA also reportedly issued a Complete Response Letter to PepGen in August 2024, citing concerns about the Company’s manufacturing processes for the drug. These developments have caused significant volatility in PepGen’s stock price.
Conclusion
As of now, the investigation is ongoing, and no definitive conclusions have been reached. However, it is important for investors to be aware of the situation and their potential options for recovery if misconduct is uncovered. PepGen shareholders who purchased or otherwise acquired the Company’s securities between certain dates are encouraged to contact Pomerantz LLP for a consultation.
The global implications of this investigation extend beyond the biotechnology industry, as it could set a precedent for how securities fraud cases are handled in the future. Stay tuned for updates as more information becomes available.
